Akari Therapeutics: Funding, Investors & Team (Oct 2026)
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, Nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung.
Akari Therapeutics has raised $12.8M across 1 funding round on record, the most recent a Post-IPO Equity of $12.8M announced in Sep 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Akari Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Akari Therapeutics Funding Rounds
Akari Therapeutics Founders and Leadership Team
Contact details for the Akari Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Akari Therapeutics Funding Compared to Other Biotechnology Startups
Akari Therapeutics' latest round of $12.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Akari Therapeutics in Biotechnology and London
Companies Similar to Akari Therapeutics
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Akari Therapeutics Funding FAQs
What does Akari Therapeutics do?
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, Nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung.
How much funding has Akari Therapeutics raised?
Akari Therapeutics has raised $12.8M across 1 round on record. The most recent is a Post-IPO Equity of $12.8M announced in Sep 2022.
When did Akari Therapeutics last raise funding?
Akari Therapeutics' most recent funding round on record is a Post-IPO Equity of $12.8M, announced in Sep 2022.
Who is the CEO of Akari Therapeutics?
Rachelle Jacques is listed as CEO at Akari Therapeutics.
Where is Akari Therapeutics headquartered?
Akari Therapeutics is based in London, England, United Kingdom.
How many employees does Akari Therapeutics have?
Akari Therapeutics is in the 11-50 employee band.
How does Akari Therapeutics' funding compare to other Biotechnology startups?
Akari Therapeutics' latest round of $12.8M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Akari Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Akari Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.